Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.60
+0.46 (5.65%)
At close: Sep 11, 2026, 4:00 PM EDT
8.57
-0.03 (-0.35%)
After-hours: Sep 11, 2026, 7:57 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $99.31M in the quarter ending June 30, 2026, with 65.65% growth. This brings the company's revenue in the last twelve months to $324.97M, up 34.55% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth.
Revenue (ttm)
$324.97M
Revenue Growth
+34.55%
P/S Ratio
11.99
Revenue / Employee
$333,302
Employees
975
Market Cap
3.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
IOVA News
- 2 days ago - Iovance Biotherapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 8 days ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 9 days ago - Iovance Biotherapeutics put volume heavy and directionally bearish - TheFly
- 18 days ago - Iovance Biotherapeutics price target raised to $10 from $7 at TD Cowen - TheFly
- 21 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Iovance Biotherapeutics price target raised to $7 from $4 at UBS - TheFly
- 25 days ago - Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho - TheFly
- 26 days ago - Iovance Biotherapeutics put volume heavy and directionally bearish - TheFly